CLINICAL AND VIROLOGICAL EFFECTS OF HIGH-DOSE RECOMBINANT INTERFERON-α IN DISSEMINATED AIDS-RELATED KAPOSI'S SARCOMA

Ronald De Wit; Charles A.B. Boucher; Kees H.N. Veenhof; Jan K.M.E. Schattenkerk; Piet J.M. Bakker; Sven A. Danner

doi:10.1016/S0140-6736(88)90810-0

CLINICAL AND VIROLOGICAL EFFECTS OF HIGH-DOSE RECOMBINANT INTERFERON-α IN DISSEMINATED AIDS-RELATED KAPOSI'S SARCOMA

Ronald De Wit^*, Charles A.B. Boucher, Kees H.N. Veenhof, Jan K.M.E. Schattenkerk, Piet J.M. Bakker, Sven A. Danner

^*Corresponding author for this work

Internal medicine

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The effectiveness and antiretroviral activities of interferon-α in AIDS-related Kaposi's sarcoma was assessed in a non-randomised, phase-II clinical trial. 28 patients were treated with high-dose (27-36 MU) human recombinant interferon-α_2a subcutaneously every day for 8 weeks. In patients with stable disease or showing a response, treatment was continued three times weekly until a complete response was achieved or there was progression. 12 of the 26 evaluable patients achieved a major response; 5 of these showed histologically confirmed complete responses. There was a significant increase in OKT4-positive cells in the responders and a significant decrease in HIV antigen (HIV-Ag) in the 7 responders with initially detectable HIV-Ag. Interferon-α is thus an effective treatment. The increase in OKT4-positive cells and the decrease in HIV-Ag seem to be significantly related to patients with tumour responses.

Original language	English
Pages (from-to)	1214-1217
Number of pages	4
Journal	The Lancet
Volume	332
Issue number	8622
DOIs	https://doi.org/10.1016/S0140-6736(88)90810-0
Publication status	Published - 26 Nov 1988

Access to Document

10.1016/S0140-6736(88)90810-0

Link to publication in Scopus

Cite this

@article{0a390551e1c24dc6a8de49a4aa0849f6,

title = "CLINICAL AND VIROLOGICAL EFFECTS OF HIGH-DOSE RECOMBINANT INTERFERON-α IN DISSEMINATED AIDS-RELATED KAPOSI'S SARCOMA",

abstract = "The effectiveness and antiretroviral activities of interferon-α in AIDS-related Kaposi's sarcoma was assessed in a non-randomised, phase-II clinical trial. 28 patients were treated with high-dose (27-36 MU) human recombinant interferon-α2a subcutaneously every day for 8 weeks. In patients with stable disease or showing a response, treatment was continued three times weekly until a complete response was achieved or there was progression. 12 of the 26 evaluable patients achieved a major response; 5 of these showed histologically confirmed complete responses. There was a significant increase in OKT4-positive cells in the responders and a significant decrease in HIV antigen (HIV-Ag) in the 7 responders with initially detectable HIV-Ag. Interferon-α is thus an effective treatment. The increase in OKT4-positive cells and the decrease in HIV-Ag seem to be significantly related to patients with tumour responses.",

author = "{De Wit}, Ronald and Boucher, {Charles A.B.} and Veenhof, {Kees H.N.} and Schattenkerk, {Jan K.M.E.} and Bakker, {Piet J.M.} and Danner, {Sven A.}",

year = "1988",

month = nov,

day = "26",

doi = "10.1016/S0140-6736(88)90810-0",

language = "English",

volume = "332",

pages = "1214--1217",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8622",

}

CLINICAL AND VIROLOGICAL EFFECTS OF HIGH-DOSE RECOMBINANT INTERFERON-α IN DISSEMINATED AIDS-RELATED KAPOSI'S SARCOMA. / De Wit, Ronald; Boucher, Charles A.B.; Veenhof, Kees H.N.; Schattenkerk, Jan K.M.E.; Bakker, Piet J.M.; Danner, Sven A.

In: The Lancet, Vol. 332, No. 8622, 26.11.1988, p. 1214-1217.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - CLINICAL AND VIROLOGICAL EFFECTS OF HIGH-DOSE RECOMBINANT INTERFERON-α IN DISSEMINATED AIDS-RELATED KAPOSI'S SARCOMA

AU - De Wit, Ronald

AU - Boucher, Charles A.B.

AU - Veenhof, Kees H.N.

AU - Schattenkerk, Jan K.M.E.

AU - Bakker, Piet J.M.

AU - Danner, Sven A.

PY - 1988/11/26

Y1 - 1988/11/26

N2 - The effectiveness and antiretroviral activities of interferon-α in AIDS-related Kaposi's sarcoma was assessed in a non-randomised, phase-II clinical trial. 28 patients were treated with high-dose (27-36 MU) human recombinant interferon-α2a subcutaneously every day for 8 weeks. In patients with stable disease or showing a response, treatment was continued three times weekly until a complete response was achieved or there was progression. 12 of the 26 evaluable patients achieved a major response; 5 of these showed histologically confirmed complete responses. There was a significant increase in OKT4-positive cells in the responders and a significant decrease in HIV antigen (HIV-Ag) in the 7 responders with initially detectable HIV-Ag. Interferon-α is thus an effective treatment. The increase in OKT4-positive cells and the decrease in HIV-Ag seem to be significantly related to patients with tumour responses.

AB - The effectiveness and antiretroviral activities of interferon-α in AIDS-related Kaposi's sarcoma was assessed in a non-randomised, phase-II clinical trial. 28 patients were treated with high-dose (27-36 MU) human recombinant interferon-α2a subcutaneously every day for 8 weeks. In patients with stable disease or showing a response, treatment was continued three times weekly until a complete response was achieved or there was progression. 12 of the 26 evaluable patients achieved a major response; 5 of these showed histologically confirmed complete responses. There was a significant increase in OKT4-positive cells in the responders and a significant decrease in HIV antigen (HIV-Ag) in the 7 responders with initially detectable HIV-Ag. Interferon-α is thus an effective treatment. The increase in OKT4-positive cells and the decrease in HIV-Ag seem to be significantly related to patients with tumour responses.

UR - http://www.scopus.com/inward/record.url?scp=0023739085&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(88)90810-0

DO - 10.1016/S0140-6736(88)90810-0

M3 - Article

C2 - 2903953

AN - SCOPUS:0023739085

VL - 332

SP - 1214

EP - 1217

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 8622

ER -